The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 21 | — | 20.1x | Below average | |
Growth | 88 | 95.3% | 5.6% | Above average | |
Quality | 52 | 2.4% | 7.6% | Near average | |
Safety | 39 | 10.9x | 0.4x | Near average | |
Capital Return | 38 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Arcutis Biotherapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Arcutis Biotherapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Arcutis Biotherapeutics stock has seen a downward revision in its average target price by 4.23% over the past 30 days, as the consensus dropped from 35.5 dollars to 34 dollars. Notably, the Analyst Dispersion among the seven analysts has completely disappeared, with the high and low targets converging at 34 dollars, indicating a rare case of absolute consensus on the stock's fair value despite the lowered expectations.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.